Intuitive Surgical, Inc.
$74.7M 126,596 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Gilead Sciences, Inc.
Gilead Sciences, Inc. reported $72,668,586.58 across General Payments, Research, and Ownership to 118,932 physicians and teaching hospitals across 121,377 transactions.
- $72.7M
- All-tracks total
- 121,377
- Transactions
- 118,932
- Recipients
- +$3.5M
- General Payments vs PY2023
Gilead Sciences, Inc. reported $72,668,586.58 across all CMS Open Payments tracks (General + Research + Ownership) to 118,932 physicians and teaching hospitals in Program Year 2024 - ranking #39 of 1,925 reporting manufacturers (0.5% of the all-tracks industry total); General Payments alone were $39,607,599.13, averaging $611.01 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer gilead-sciences-inc Gilead Sciences, Inc.
$72.7M · #39/1,925 · 0.5% industry · PY2024
- TOT $72.7M
- RANK #39
- SHARE 0.5%
- TXN 121,377
- RCP 118,932
- CAT 8
- GEN $39.6M
- ΔGEN +$3.5M
- TOP1 10.8%
- PY 2024
Volume peers
Nearest volume peer: Intuitive Surgical, Inc. ($74.7M)
Gilead Sciences, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Gilead Sciences, Inc.'s CMS-reported General Payments increased by $3.5M (+9.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GILEAD SCIENCES, INC.PY2023: GILEAD SCIENCES, INC.PY2024: Gilead Sciences, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $36,066,155.66
- PY2024
- $39,607,599.13
What the Data Shows for Gilead Sciences, Inc.
Rank #39 of 1,925 companies in CMS Open Payments for 2024 belongs to Gilead Sciences, Inc., which reported $72,668,586.58 across 121,377 transactions to 118,932 recipients - representing 0.5% of all industry payments reported nationwide for the year. Averages work out to $598.70 per transaction and $611.01 per recipient.
"Grant" leads the 8-category general-payment breakdown below at $15.7M (39.7% of General Payments, 196 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Gilead Sciences, Inc. made 8 types of general payments. "Grant" is the largest category at $15.7M, 39.7% of General Payments.
Gilead Sciences, Inc. reports 8 general-payment categories - the top three are Grant (39.7%), Compensation for Services Other Than Consulting (26.8%), and Consulting Fee (13.6%). The remaining 5 categories make up 19.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Gilead Sciences, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Gilead Sciences, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Grant | $15.7M | 196 | 39.7% |
| Compensation for Services Other Than Consulting | $10.6M | 4,256 | 26.8% |
| Consulting Fee | $5.4M | 1,169 | 13.6% |
| Food and Beverage | $3.6M | 106,181 | 9.1% |
| Travel and Lodging | $2.5M | 6,561 | 6.4% |
| Royalty or License | $1.1M | 11 | 2.9% |
| Space Rental or Facility Fees | $588.8K | 163 | 1.5% |
| Education | $32.6K | 395 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $8,252,580.49 (20.8%) of $39,607,599.13 in this company's General Payments records across 30,271 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Gilead Sciences, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Emory University Hospital
$4,269,910.88 across 21 reported transactions
- 2
Ochsner Clinic Foundation
$1,465,691.70 across 25 reported transactions
- 3
University Of Washington Med Ctr
$1,201,838.91 across 17 reported transactions
- 4
Ph Patewood Hospital
$701,326.00 across 6 reported transactions
- 5
Hackensack University Medical Center
$613,813.00 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Gilead Sciences, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Gilead Sciences, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Gilead Sciences, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Innovation Technologies Inc
$75.8M 3,361 recipients
Compare payment profiles
BeiGene, Ltd.
$77.4M 57 recipients
Compare payment profiles
Teva Pharmaceuticals USA, Inc.
$67.4M 141,158 recipients
Compare payment profiles
Advanced Accelerator Applications
$63.9M 167 recipients
Compare payment profiles
Servier BioInnovation
$83.4M 11 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.